Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease with poor prognosis. Adipose-derived stem cells (ADSC) have demonstrated regenerative properties in several tissues. The hypothesis of this study was that airway transplantation of ADSC could protect against bleomycin (BLM)-induced pulmonary fibrosis (PF). Fifty-eight lungs from 29 male Sprague-Dawley rats were analyzed. Animals were randomly divided into five groups: a) control (n=3); b) sham (n=6); c) BLM (n=6); d) BLM+ADSC-2d (n=6); and e) BLM+ADSC-14d (n=8). Animals received 500 µL saline (sham), 2.5 UI/kg BLM in 500 µL saline (BLM), and 2×106 ADSC in 100 µL saline intratracheally at 2 (BLM+ADSC-2d) and 14 days (BLM+ADSC-14d) after BLM. Animals were sacrificed at 28 days. Blinded Ashcroft score was used to determine pulmonary fibrosis extent on histology. Hsp27, Vegf, Nfkβ, IL-1, IL-6, Col4, and Tgfβ1 mRNA gene expression were determined using real-time quantitative-PCR. Ashcroft index was: control=0; sham=0.37±0.07; BLM=6.55±0.34 vs sham (P=0.006). BLM vs BLM+ADSC-2d=4.63±0.38 (P=0.005) and BLM+ADSC-14d=3.77±0.46 (P=0.005). BLM vs sham significantly increased Hsp27 (P=0.018), Nfkβ (P=0.009), Col4 (P=0.004), Tgfβ1 (P=0.006) and decreased IL-1 (P=0.006). BLM+ADSC-2d vs BLM significantly decreased Hsp27 (P=0.009) and increased Vegf (P=0.006), Nfkβ (P=0.009). BLM+ADSC-14d vs BLM significantly decreased Hsp27 (P=0.028), IL-6 (P=0.013), Col4 (P=0.002), and increased Nfkβ (P=0.040) and Tgfβ1 (P=0.002). Airway transplantation of ADSC significantly decreased the fibrosis rate in both early and established pulmonary fibrosis, modulating the expression of Hsp27, Vegfa, Nfkβ, IL-6, Col4, and Tgfβ1. From a translational perspective, this technique could become a new adjuvant treatment for patients with IPF.
American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med2000;161:646–64.doi:10.1164/ajrccm.161.2.ats3-00
RaghuG, CollardHR, EganJJ, . An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med2011;183:788–824.doi:10.1164/rccm.2009-040GL
4.
LeungJ, ChoY, LockeyRF, . The role of aging in idiopathic pulmonary fibrosis. Lung2015;193:605–10.doi:10.1007/s00408-015-9729-3
5.
SelmanM, PardoA. Revealing the pathogenic and aging-related mechanisms of the enigmatic idiopathic pulmonary fibrosis. an integral model. Am J Respir Crit Care Med2014;189:1161–72.doi:10.1164/rccm.201312-2221PP
LamasDJ, KawutSM, BagiellaE, . Delayed access and survival in idiopathic pulmonary fibrosis: a cohort study. Am J Respir Crit Care Med2011;184:842–7.doi:10.1164/rccm.201104-0668OC
MatsumotoD, SatoK, GondaK, . Cell-assisted lipotransfer: supportive use of human adipose-derived cells for soft tissue augmentation with lipoinjection. Tissue Eng2006;12:3375–82.doi:10.1089/ten.2006.12.3375
10.
SchweitzerKS, JohnstoneBH, GarrisonJ, . Adipose stem cell treatment in mice attenuates lung and systemic injury induced by cigarette smoking. Am J Respir Crit Care Med2011;183:215–25.doi:10.1164/rccm.201001-0126OC
11.
LeeSH, LeeEJ, LeeSY, . The effect of adipose stem cell therapy on pulmonary fibrosis induced by repetitive intratracheal bleomycin in mice. Exp Lung Res2014;40:117–25.doi:10.3109/01902148.2014.881930
12.
TashiroJ, ElliotSJ, GerthDJ, . Therapeutic benefits of young, but not old, adipose-derived mesenchymal stem cells in a chronic mouse model of bleomycin-induced pulmonary fibrosis. Transl Res2015;166:554–67.doi:10.1016/j.trsl.2015.09.004
13.
GhadiriM, YoungPM, TrainiD. Cell-based therapies for the treatment of idiopathic pulmonary fibrosis (IPF) disease. Expert Opin Biol Ther2016;16:375–87.doi:10.1517/14712598.2016.1124085
14.
BrownRF, DrawbaughRB, MarrsTC. An investigation of possible models for the production of progressive pulmonary fibrosis in the rat. The effects of repeated intratracheal instillation of bleomycin. Toxicology1988;51:101–10.doi:10.1016/0300-483X(88)90084-4
15.
DominiciM, Le BlancK, MuellerI, . Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy2006;8:315–7.doi:10.1080/14653240600855905
16.
ZuñigaJM, Tur MaríJA, MiloccoSN, . Ciencia y tecnología en protección y experimentación animal. McGraw-Hill Interamericana: Madrid-España, 2001.
17.
AshcroftT, SimpsonJM, TimbrellV. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol1988;41:467–70.doi:10.1136/jcp.41.4.467
18.
De LangheE, Vande VeldeG, HostensJ, . Quantification of lung fibrosis and emphysema in mice using automated micro-computed tomography. PLoS One2012;7:e43123.doi:10.1371/journal.pone.0043123
19.
AusubelFM, BrentR, KingstonRE, . Current protocols in molecular biology. New York: John Wiley and Sons, 1987.
20.
RozenS, SkaletskyH. Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol2000;132:365–86.
21.
PfafflMW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res2001;29:45e–45.doi:10.1093/nar/29.9.e45
22.
Karimi-ShahBA, ChowdhuryBA. Forced vital capacity in idiopathic pulmonary fibrosis–FDA review of pirfenidone and nintedanib. N Engl J Med2015;372:1189–91.doi:10.1056/NEJMp1500526
23.
BlackwellTS, TagerAM, BorokZ, . Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report. Am J Respir Crit Care Med2014;189:214–22.doi:10.1164/rccm.201306-1141WS
24.
Serrano-MollarA. [Alveolar epithelial cell injury as an etiopathogenic factor in pulmonary fibrosis]. Arch Bronconeumol2012;48 Suppl 2(Suppl 2):2–6.doi:10.1016/S0300-2896(12)70044-3
25.
AguilarS, ScottonCJ, McNultyK, . Bone marrow stem cells expressing keratinocyte growth factor via an inducible lentivirus protects against bleomycin-induced pulmonary fibrosis. PLoS One2009;4:e8013.doi:10.1371/journal.pone.0008013
26.
OrtizLA, GambelliF, McBrideC, . Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci U S A2003;100:8407–11.doi:10.1073/pnas.1432929100
27.
RenX, MoserPT, GilpinSE, . Engineering pulmonary vasculature in decellularized rat and human lungs. Nat Biotechnol2015;33:1097–102.doi:10.1038/nbt.3354
28.
WettsteinG, BellayePS, KolbM, . Inhibition of HSP27 blocks fibrosis development and EMT features by promoting Snail degradation. Faseb J2013;27:1549–60.doi:10.1096/fj.12-220053
29.
VidyasagarA, ReeseSR, HafezO, . Tubular expression of heat-shock protein 27 inhibits fibrogenesis in obstructive nephropathy. Kidney Int2013;83:84–92.doi:10.1038/ki.2012.336
30.
Santana-RodríguezN, García-HerreraR, ClavoB, . Searching for novel molecular targets of chronic rejection in an orthotopic experimental lung transplantation model. J Heart Lung Transplant2012;31:213–21.doi:10.1016/j.healun.2011.11.011
31.
Santana-RodríguezN, LlontopP, ClavoB, . Ozone therapy protects against rejection in a lung transplantation model: a new treatment?Ann Thorac Surg2017;104:458–64.doi:10.1016/j.athoracsur.2017.02.054
32.
LiC, ZhenG, ChaiY, . RhoA determines lineage fate of mesenchymal stem cells by modulating CTGF-VEGF complex in extracellular matrix. Nat Commun2016;7:11455.doi:10.1038/ncomms11455
GhadamiM, MakitaY, YoshidaK, . Genetic mapping of the camurati-engelmann disease locus to chromosome 19q13.1-q13.3. Am J Hum Genet2000;66:143–7.doi:10.1086/302728
35.
HetzelM, BachemM, AndersD, . Different effects of growth factors on proliferation and matrix production of normal and fibrotic human lung fibroblasts. Lung2005;183:225–37.doi:10.1007/s00408-004-2534-z
36.
RibeiroA, BronkSF, RobertsPJ, . The transforming growth factor beta(1)-inducible transcription factor TIEG1, mediates apoptosis through oxidative stress. Hepatology1999;30:1490–7.doi:10.1002/hep.510300620
37.
JohnstonCJ, SmythDJ, DresserDW, . TGF-β in tolerance, development and regulation of immunity. Cell Immunol2016;299:14–22.doi:10.1016/j.cellimm.2015.10.006
38.
GilmoreTD. Introduction to NF-kappaB: players, pathways, perspectives. Oncogene2006;25:6680–4.doi:10.1038/sj.onc.1209954
39.
RahmanI, MacNeeW. Role of transcription factors in inflammatory lung diseases. Thorax1998;53:601–12.doi:10.1136/thx.53.7.601
40.
AlbensiBC, MattsonMP. Evidence for the involvement of TNF and NF-kappaB in hippocampal synaptic plasticity. Synapse2000;35:151–9.doi:10.1002/(SICI)1098-2396(200002)35:2<151::AID-SYN8>3.0.CO;2-P
41.
GargA, AggarwalBB. Nuclear transcription factor-kappaB as a target for cancer drug development. Leukemia2002;16:1053–68.doi:10.1038/sj.leu.2402482
42.
SethiG, SungB, AggarwalBB. Nuclear factor-kappaB activation: from bench to bedside. Exp Biol Med2008;233:21–31.doi:10.3181/0707-MR-196
43.
CrisostomoPR, WangY, MarkelTA, . Human mesenchymal stem cells stimulated by TNF-alpha, LPS, or hypoxia produce growth factors by an NF kappa B- but not JNK-dependent mechanism. Am J Physiol Cell Physiol2008;294:C675–C682.doi:10.1152/ajpcell.00437.2007
44.
SaitoF, TasakaS, InoueK, . Role of interleukin-6 in bleomycin-induced lung inflammatory changes in mice. Am J Respir Cell Mol Biol2008;38:566–71.doi:10.1165/rcmb.2007-0299OC
45.
AgustíC, XaubetA. [Current status of the treatment of idiopathic pulmonary fibrosis]. Arch Bronconeumol1998;34:517–9.
46.
KasugaI, YonemaruM, KiyokawaH, . Clinical evaluation of serum type IV collagen 7S in idiopathic pulmonary fibrosis. Respirology1996;1:277–81.doi:10.1111/j.1440-1843.1996.tb00043.x
47.
Teles-GriloML, Leite-AlmeidaH, Martins dos SantosJ, . Differential expression of collagens type I and type IV in lymphangiogenesis during the angiogenic process associated with bleomycin-induced pulmonary fibrosis in rat. Lymphology2005;38:130–5.
48.
VittalR, MicklerEA, FisherAJ, . Type V collagen induced tolerance suppresses collagen deposition, TGF-β and associated transcripts in pulmonary fibrosis. PLoS One2013;8:e76451.doi:10.1371/journal.pone.0076451
49.
ZhouW, WangY. Candidate genes of idiopathic pulmonary fibrosis: current evidence and research. Appl Clin Genet2016;9:5–13.doi:10.2147/TACG.S61999
